MR Imaging Biomarkers in Oncology Clinical Trials

Authors

Richard G. Abramson, Vanderbilt University
Lori R. Arlinghaus, Vanderbilt University
Adrienne N. Dula, Vanderbilt University
C. Chad Quarles, Vanderbilt University
Ashley M. Stokes, Vanderbilt University
Jared A. Weis, Vanderbilt University
Jennifer G. Whisenant, Vanderbilt University
Eduard Y. Chekmenev, Vanderbilt University
Igor Zhukov, National Research Nuclear University MEPhI
Jason M. Williams, Vanderbilt University
Thomas E. Yankeelov, Vanderbilt University

Document Type

Article

Abstract

The authors discuss eight areas of quantitative MR imaging that are currently used (RECIST, DCE-MR imaging, DSC-MR imaging, diffusion MR imaging) in clinical trials or emerging (CEST, elastography, hyperpolarized MR imaging, multiparameter MR imaging) as promising techniques in diagnosing cancer and assessing or predicting response of cancer to therapy. Illustrative applications of the techniques in the clinical setting are summarized before describing the current limitations of the methods.

Keywords

CEST, DCE-MR imaging, Diffusion, DSC-MR imaging, Elastography, Hyperpolarized, Multiparametric

Publication Date

2-1-2016

Publication Title

Magnetic Resonance Imaging Clinics of North America

ISSN

10649689

E-ISSN

15579786

Volume

24

Issue

1

First Page

11

Last Page

29

PubMed ID

26613873

Digital Object Identifier (DOI)

10.1016/j.mric.2015.08.002

Recommended Citation

Abramson, Richard G.; Arlinghaus, Lori R.; Dula, Adrienne N.; Quarles, C. Chad; Stokes, Ashley M.; Weis, Jared A.; Whisenant, Jennifer G.; Chekmenev, Eduard Y.; Zhukov, Igor; Williams, Jason M.; and Yankeelov, Thomas E., "MR Imaging Biomarkers in Oncology Clinical Trials" (2016). Translational Neuroscience. 1192.
https://scholar.barrowneuro.org/neurobiology/1192